SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong quarterly results and raised outlook were followed by a selloff, with traders focused on slower contract bookings and whether growth can justify the stocks high valuation. Bulls view the pullback as an overreaction to an otherwise strong business update, while bears see the bookings trend and premium valuation as reasons for caution.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A record fiscal-quarter report and raised revenue outlook, supported by strong AI-chip testing demand, drove AEHRs sharp rebound after a prolonged selloff. Many traders welcomed the results and discussed further AI-driven orders or a short squeeze, while skeptics warned that the stock remains expensive and could fade.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys Q3 revenue and merchandise-volume misses, alongside softer subscription metrics, triggered a sharp selloff despite an earnings beat and strong cash generation. Traders are split between viewing the drop as an overreaction and buying the rebound, and arguing that moderating growth leaves little room for a richly valued stock to disappoint.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC presentations of pipeline data, including glioblastoma findings. Bulls see the milestones as potential validation, while skeptics question the filing timeline, managements transparency and the risk of further dilution.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigals latest results marked its first profitable quarter, with continued Rezdiffra growth, but shares sold off sharply despite the strong report. Traders debate whether the decline reflects concerns about slow market penetration, reimbursement and spending, and the need for clinical-outcomes evidence, or an overreaction to strong commercial momentum.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

Strong Q3 results, faster growth in B2 Cloud Storage, and raised guidance are driving interest in Backblazes AI-storage opportunity. Traders are split between buying the earnings-driven move and expecting a sell-the-news pullback, with some questioning whether the growth can sustain the rally.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins third-quarter resultscontinued revenue growth, sharply stronger operating profitability, and record customer activityalongside a new share-repurchase program are driving discussion. Traders welcomed the results and buyback, but many remain frustrated by the muted share-price response and debate whether weak same-store sales and the OTC listing will keep the stock range-bound; relisting is viewed as a possible but uncertain longer-term catalyst.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiservs quarterly earnings beat, reaffirmed outlook, expanded cost-savings plan and planned share repurchases sparked a sharp rebound after a prolonged decline. Traders welcomed the potential turnaround and speculated about a short squeeze, while others remained cautious about margin pressure and execution risks.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transoceans Q3 results and Fleet Status Report are driving discussion, with traders debating the reported earnings and criticizing the share-price decline despite some bullish commentary on the call. The reaction is also shaped by ongoing concerns about dilution from the Valaris merger, alongside speculation about high short interest and a possible squeeze.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd.

Teva- Pharmaceutical Industries Ltd. - ADR

Tevas quarterly earnings beat, higher 2026 outlook for key innovative drugs, and a new U.S. biosimilar commercialization deal are driving attention. Traders are reacting to the stronger growth outlook and fresh share highs, while some remain cautious about the companys broader execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2026 financial results and provide a business update on Wednesday, November 11, 2026, at 4:30 p.m. ET, after...

Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar?

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL

Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent...

Alpha Cognition to Present New ZUNVEYL (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented...

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on October 1, 2026, the Compensation Committee of the Companys Board of Directors (the...

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL(Benzgalantamine) Use in Long-Term Care

Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE...

Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on September 8, 2026, the Compensation Committee of the Companys Board of Directors (the...

Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on August 31st, 2026, the Compensation Committee of the Companys Board of Directors (the...

Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates

Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (“ALPHA-1062IN”) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

Alpha Cognition Inc

Bearish Sentiment

Republicans keep both chambers

Republicans keep the House, lose the Senate

Republicans keep the Senate, lose the House

Democrats win both chambers

Stocktwits

Stocktwits Polls

$ACOG Essex specializes in small/micro-cap growth equities, focusing on identifying under-the-radar companies right before commercial acceleration. Their team targets revenue-generating healthcare/biotech firms with proprietary assets that are shifting toward profitability.

Taking a brand-new 422k-share position indicates that $ACOG's commercial ramp and de-risked profile perfectly align with their fundamental growth strategy!

JackCampbell

$ACOG 2026-10-19 13F: Essex Investment Management Co Llc bought a fully new position of 422,858 shrs  recently worth 3.806M USD!!

$ACOG Crazy that ACOG is still this unknown. In a year this will be a billion dollar company and that just will be the start.

endrow

$ACOG One of the most important points to consider relative to the data seen in the Converge study is that it helps patients get off of and/or reduce their "multi drug cocktail".

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACOG Alpha Cognition Inc

Fundamentals

Latest ACOG News